Even before receiving public funding, Wegovy has drawn much media attention in New Zealand for the dramatic difference it can make for weight loss. But with its rise in popularity has come debate about what these next-generation drugs really mean for a worsening obesity crisis and its driving causes. Last month, New Zealand’s drug-funding agency Pharmac added Wegovy to its list of medicines suitable for future public funding. If that happens – and it could quickly – the drug would initially be t